PAX4 and type 2 diabetes mellitus: Specifically, the type 2 diabetes-associated cyclin-dependent kinase inhibitor 2A, which strongly inhibits the proliferative cyclin-dependent kinase 4 (CDK4) [39], was enriched in PAX4R129W islets whereas it was decreased in PAX4 islets.